Screening
Figure 5: Proportion of HTS laboratories using HCS for primary and secondary screens © HighTech Business Decisions
strive towards improving efficiencies and develop- ing new products and technologies for life science researchers,” said Dr Todd Upton, Commercial Technology Manager, Corning Life Sciences. “We have developed and launched two glass bottom microplates (half area 96 well and 384 well) espe- cially designed for HCS applications. The high optical-quality and scratch resistant glass bottom microplates are ideal for performing high-content assays using imaging systems. The glass bottom flatness of <50µm ensures planarity for imaging devices, reduces autofocus time and increases throughput. We are now gearing up for a summer 2013 launch of superior quality COC (Cyclic Olefin Copolymer) film-bottom microplates to complement the glass bottom HCS microplate product line. Both glass and COC bottom offer unique advantages of low auto-fluorescence and low diffusion of fluorescent detection; therefore, leading to high signals and low background. These attributes are particularly advantageous in enabling assays that typically have low emission intensity, therefore, expanding the applicability of high content imaging.”
There has also been improvements in the devel- opment of reagents for use in HCS. “We have con- sistently validated new reagents on at least one high-content platform. Examples include CellRox (oxidative stress) and CellEvent (apoptosis). We have also generated data supporting the utility of
56
established reagents in a high-content setting, for instance Alexa Fluor® labelled phalloidin actin markers,” said Dr Magnus Persmark, Senior Product Manager, Imaging, at Life Technologies.
Future use of HCS
The use of HCS will continue to continue to increase. Forty-four percent of the HTS Directors in our study expect to increase their use of HCS at their laboratories. For HTS laboratories that do not currently use HCS, one-third of the HTS Directors surveyed in our study expect to add HCS in the coming years. Furthermore, the HTS Directors, on average, plan a 13% increase in the number of wells read per week over the next two years. In addition, there continues to be interest in using HCS for primary screens. Selected comments regarding adoption of HCS, as provided by HTS directors surveyed are shown below:
“We don’t have HCS yet, but we are investigating it seriously. We plan to bring in a system within six to 18 months.”
Pharma/Biotech HTS Lab
“We are just starting to be interested in HCS, but have not yet run a screen. We will use HCS as a fol- low-up to a secondary assay. We will start running HCS primary screens within six months.”
Pharma/Biotech HTS Lab Drug Discovery World Spring 2013
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80